<DOC>
	<DOC>NCT02893826</DOC>
	<brief_summary>Safety and Pharmacokinetic study comparing intracisternal EG-1962 to enternal nimopidine in the treatment of aneurysmal subarachnoid hemorrhage.</brief_summary>
	<brief_title>Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Nimodipine</mesh_term>
	<criteria>1. Ruptured saccular aneurysm repaired by neurosurgical clipping 2. Subarachnoid hemorrhage on computed tomography (CT) scan of grade 24 on the modified Fischer scale 3. WFNS grade 1 or 2 assessed during the Prerandomization Phase. If WFNS grade 2, must not require an EVD prior to aneurysm repair 1. Major complication during aneurysm repair such as, but not limited to, massive intraoperative hemorrhage, brain swelling, arterial occlusion or inability to secure the ruptured aneurysm 2. Angiographic vasospasm prior to randomization 3. Evidence of cerebral infarction with neurological deficit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Aneurysm</keyword>
	<keyword>Ruptured</keyword>
	<keyword>nimodipine</keyword>
	<keyword>subarachnoid hemorrhage</keyword>
</DOC>